Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia
-
By
-
Nan Huang
-
Zheng Liu
-
Ronghui Li
-
Haibo Lei
-
Xiang Liu
-
May 14, 2026
-
Clinical Scorecard: Characteristics, Management, and Prognosis of Immune Thrombocytopenia Induced by Oxaliplatin
At a Glance
| Category | Detail |
|---|
| Condition | Oxaliplatin-Induced Immune Thrombocytopenia (OITP) |
| Key Mechanisms | Type II hypersensitivity response mediated by drug-dependent antibodies against platelet glycoproteins. |
| Target Population | Patients undergoing oxaliplatin-based chemotherapy, primarily those with colorectal cancer. |
| Care Setting | Oncology clinics and hospitals administering chemotherapy. |
Key Highlights
- OITP occurs after cumulative exposure to oxaliplatin, often misidentified as typical myelosuppression.
- Severe thrombocytopenia (< 25×10^9/L) observed in 82.5% of patients.
- Immediate cessation of oxaliplatin is critical upon diagnosis.
- Primary management includes glucocorticoids and platelet transfusion.
- Overall recovery rate is 92.5%, with a median recovery duration of 7 days.
Guideline-Based Recommendations
Diagnosis
- Identify acute thrombocytopenia in patients receiving oxaliplatin.
- Differentiate OITP from typical myelosuppression and consumptive thrombocytopenia.
Management
- Cease oxaliplatin immediately.
- Administer glucocorticoids and platelet transfusions as first-line treatments.
Monitoring & Follow-up
- Regularly monitor platelet counts in patients receiving oxaliplatin.
Risks
- Increased risk of severe thrombocytopenia and hemorrhagic symptoms.
- Mortality rate associated with OITP is 7.5%.
Patient & Prescribing Data
Predominantly female patients with colorectal cancer, median age 59 years.
OITP may present after multiple chemotherapy cycles, necessitating careful monitoring.
Clinical Best Practices
- Educate healthcare providers on recognizing OITP symptoms.
- Implement immediate cessation of oxaliplatin upon diagnosis of OITP.
- Consider plasma exchange for refractory or life-threatening cases.
Related Resources & Content
